Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism

British Journal of Clinical Pharmacology

Volumn 54, Issue 5, 2002, Pages 511-517

  Yoshida, Ryoko ^a   Nakajima, Miki ^a   Watanabe, Yuki ^a   Kwon, Jun Tack ^a   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Cytochrome P450; Genetic polymorphism; Genotype; Interindividual difference; Nicotine metabolism; Phenotype; Poor metabolizer

Indexed keywords

COTININE; CYTOCHROME P450 2A6; NICOTINE GUM;

ALLELE; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG BLOOD LEVEL; DRUG METABOLISM; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HUMAN; IN VIVO STUDY; JAPAN; KOREA; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ARYL HYDROCARBON HYDROXYLASES; BASE SEQUENCE; GANGLIONIC STIMULANTS; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; JAPAN; KOREA; MIXED FUNCTION OXYGENASES; NICOTINE; NICOTINIC AGONISTS; POLYMETHACRYLIC ACIDS; POLYMORPHISM, GENETIC; POLYVINYLS; SEQUENCE ANALYSIS, DNA;

EID: 0036435654     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01667.x     Document Type: Article

References (21)

1. Oscarson M. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: Implications for interindividual differences in nicotine metabolism. Drug Metab Dispos 2001; 29: 91-95.
2. Nakajima M, Yamamoto T, Nunoya K-I, et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 1996; 24: 1212-1217.
3. Nakajima M, Yamamoto T, Nunoya K-I, et al. Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther 1996; 277: 1010-1015.
4. Cholerton S, Arpanahi A, McCracken N, et al. Poor metabolisers of nicotine and CYP2D6 polymorphism. Lancet 1994; 343: 62-63.
5. Benowitz NL, Jacob PIII, Sachs DPL. Deficient C-oxidation of nicotine. Clin Pharmacol Ther 1995; 57: 590-594.
6. Nakajima M, Yamagishi S-I, Yamamoto H, et al. Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans. Clin Pharmacol Ther 2000; 67: 57-69.
7. Nakajima M, Kwon J-T, Tanaka N, et al. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin Pharmacol Ther 2001; 69: 72-78.
8. Kwon J-T, Nakajima M, Chai S, et al. Nicotine metabolism and CYP2A6 allele frequencies in Koreans. Pharmacogenetics 2001; 11: 317-323.
9. Oscarson M, McLellan RA, Gullstén H, et al. Identification and characterisation of novel polymorphisms in the CYP2A locus: Implications for nicotine metabolism. FEBS Lett 1999; 460: 321-327.
10. Yamano S, Tatsuno J, Gonzalez FJ. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 1990; 29: 1322-1329.
11. Fernandez-Salguero P, Hoffman SMG, Cholerton S, et al. A genetic polymorphism in coumarin 7-hydroxylation: Sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet 1995; 57: 651-660.
12. Nunoya K-I, Yokoi T, Takahashi Y, et al. Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype. J Biochem 1999; 126: 402-407.
13. Oscarson M, McLellan RA, Gullstén H, et al. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett 1999; 448: 105-110.
14. Kitagawa K, Kunugita N, Kitagawa M, Kawamoto T. CYP2A6*6, a novel polymorphism in cytochrome P450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity. J Biol Chem 2001; 276: 17830-17835.
15. Ariyoshi N, Sawamura Y, Kamataki T. A novel single nucleotide polymorphism altering stability and activity of CYP2A6. Biochem Biophys Res Commun 2001; 281: 810-814.
16. Rao Y, Hoffmann E, Zia H, et al. Duplications and defects in the CYP2A6 gene: Identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 2000; 58: 747-755.
17. Daigo S, Takahashi Y, Ariyoshi N, et al. Genotyping of CYP2A6 gene in patient whose pharmacokinetics of tegafur was abnormal. Xenobio Metab Dispos 2000; 15: S209.
18. Nakajima M, Yamamoto T, Kuroiwa Y, Yokoi T. Improved highly sensitive method for determination of nicotine and cotinine in human plasma by high-performance liquid chromatography. J Chromatogr B 2000; 742: 211-215.
19. Finney DJ. Probit Analysis. London: Cambridge University Press, 1964.
20. Oscarson M, Gullstén H, Rautio A, et al. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett 1998; 438: 201-205.
21. Ariyoshi N, Takahashi Y, Miyamoto M, et al. Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C. Pharmacogenetics 2000; 10: 687-693.